Home
Journals
A-Z Journals
Browse By Subject
Guidelines & Policies
Editorial Policies
Online Submission
Instructions to Authors
Policies
Publication ethics & malpractice statement
Reviewers
Terms and Conditions
Advertising
Conferences
Contact us
Drug Designing: Open Access
Open Access
ISSN: 2169-0138
Journal Home
Editorial Panel
Editor-in-Chief
Editorial Board
Instructions for Authors
Instructions for Authors
Publication ethics & malpractice statement
Submit Manuscript
Aims and Scope
Articles in process
Archive
Special Issues
Guidelines
Upcoming Special Issues
Contact
Abstract
The Success of Solanezumab Should Drive Renewed Efforts to Develop Small Molecule Anti-Amyloid Agents for Alzheimer's disease Therapy.
Anthony R White
Share this article
Top
